...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
Biology Products:... argued about how birds evolved the ability to fly, ... fitness would result from ancestral, partly evolved wings. Two ... flight evolved in tree-dwelling ancestors that used their forelimbs ... birds to be terrestrial dinosaurs that developed powered flight ...
... largest HIV/AIDS therapy studies conducted to date show ... more than doubles the risk of AIDS or ... Mailman School of Public Health and Harlem Hospital ... as Strategies for Management of Anti-Retroviral Therapies, or ...
... the infection rate of three viruses ?and risk of death ... be reported in the Nov. 1 print edition of Nature ... Medicine, The Methodist Hospital, and Texas Children's Hospital. , ... phase 1 trial, funded by the National Heart, Lung, and ...
Other Biology News:Protowings may have helped bird ancestors cover rough terrain 2Study shows interruption of antiretroviral therapy increases risk of disease and death 2Study shows interruption of antiretroviral therapy increases risk of disease and death 3Three-in-one virus killer prevents common, often fatal infections 2(Date:12/14/2009)... 14 The third edition of ... , published by the Infusion Nurses Society ... anthracycline extravasation.(1) Anthracyclines are a group of ... that have been used in the treatment of ... ,, According to the INS publication: ...
(Date:12/14/2009)... Decision Resources, one of the world,s ... healthcare issues, finds that, owing to the launches ... market will increase more than sevenfold from $790 ... in the United States, France, Germany, Italy, Spain, ... Pharmacor report entitled Atrial Fibrillation finds ...
(Date:12/11/2009)... -- Dendreon Corporation (Nasdaq: DNDN ) announced ... public offering have exercised in full their option ... stock at the public offering price of $24.75 ... increases the size of the offering to an ... Dendreon expects to receive net proceeds from the ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment ... Anderson Cancer Center of the first patient in the ... E fficacy) Phase 2 pivotal trial in patients ... AC220 is a novel, orally available, potent and highly ... FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE study ...
Breaking Biology Technology:Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Biology NavigationMedical Navigation